Bradley Keller
11Patents
7h-index
14Co-inventors
63Inventor score
Filing activity: Mar 9, 1998 → Feb 22, 2019
Most-cited inventions
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US6943189B2 | Combination therapy employing ileal bile acid transport inhibiting benzothiepines and HMG CO-A reductase inhibitors | Chemistry; Metallurgy | 69 | Expired |
| US6562860B1 | Combinations of ileal bile acid transport inhibitors and bile acid sequestering agents for cardiovascular indications | Human Necessities | 35 | Expired |
| US6420417B1 | Combination therapy employing ileal bile acid transport inhibiting benzothiepines and HMG Co-A reductase inhibitors | Chemistry; Metallurgy | 21 | Expired |
| US6268392A | Combination therapy employing ileal bile acid transport inhibiting benzothiepines and HMG Co-A reductase inhibitors | Chemistry; Metallurgy | 19 | Expired |
| US6642268B2 | Combination therapy employing ileal bile acid transport inhibiting benzothipines and HMG Co-A reductase inhibitors | Chemistry; Metallurgy | 17 | Expired |
| US8710191B2 | Antibodies to CCR2 | Chemistry; Metallurgy | 16 | Active |
| US6458851B1 | Combinations of ileal bile acid transport inhibitors and cholesteryl ester transfer protein inhibitors for cardiovascular indications | Human Necessities | 13 | Expired |
| US6462091B1 | Combinations of cholesteryl ester transfer protein inhibitors and HMG coA reductase inhibitors for cardiovascular indications | Human Necessities | 4 | Expired |
| US11389456B2 | Compounds and methods for treating oxalate-related diseases | Human Necessities | 1 | Active |
| US6638969B1 | Combinations of ileal bile acid transport inhibitors and fibric acid derivatives for cardiovascular indications | Human Necessities | 1 | Expired |
| US9238691B2 | Nucleic acids encoding antibodies to CCR2 | Chemistry; Metallurgy | 0 | Active |
Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.